Short-term versus long-term hormone therapy plus radiotherapy or prostatectomy for prostate cancer: A systematic review and meta-analysis

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 5, 2013, Pages 783-796

  Zhou, Zhi Rui ^a   Zhu, Xiao Dong ^a   Xia, Jun ^b   Zou, Zhang Yu ^c   Qu, Song ^a   Zeng, Xian Tao ^d   Mao, Zhi ^e   Liang, Zhong Guo ^a  

^a Guangxi Cancer Institute   (China)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^d HUBEI UNIVERSITY OF MEDICINE   (China)

^e CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Hormone therapy; Meta analysis; Prostatic cancer; Radical prostatectomy; Radiotherapy

Indexed keywords

ANTIANDROGEN; HORMONE; PROSTATE SPECIFIC ANTIGEN;

BREAST DEVELOPMENT; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG TREATMENT FAILURE; FLUID RETENTION; GASTROINTESTINAL TOXICITY; HEART DISEASE; HOT FLUSH; HUMAN; IMPOTENCE; INFECTION; INTERMETHOD COMPARISON; LONG TERM CARE; MALE BREAST; META ANALYSIS; NAUSEA; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE VOLUME; PROSTATECTOMY; REVIEW; SHORT COURSE THERAPY; SIDE EFFECT; SYSTEMATIC REVIEW; THROMBOSIS; UNSPECIFIED SIDE EFFECT; UROGENITAL TRACT DISEASE; VOMITING;

ANTINEOPLASTIC AGENTS, HORMONAL; DISEASE PROGRESSION; HUMANS; MALE; ORGAN SIZE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; TREATMENT FAILURE;

EID: 84876291224     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-013-1383-7     Document Type: Review

References (39)

1. Armstrong J, Fitzpatrick D, Taylor J, Thirion P (2007) Results of a randomized trial comparing short versus protracted neoadjuvant hormonal therapy (NHT) prior to radiation therapy (RT) of localized prostate cancer. Ejc Suppl 5(4):290. doi: 10.1016/s1359-6349(07)71105-9
2. Armstrong JG, Gillham CM, Dunne MT, Fitzpatrick DA, Finn MA, Cannon ME, Taylor JC, O'Shea CM, Buckney SJ, Thirion PG (2011) A randomized trial (Irish clinical oncology research group 97-01) comparing short versus protracted neoadjuvant hormonal therapy before radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 81(1):35-45. doi: 10.1016/j.ijrobp.2010.04.065
3. Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, Vist GE, Falck-Ytter Y, Meerpohl J, Norris S, Guyatt GH (2011) GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 64(4):401-406. doi: 10.1016/j.jclinepi.2010.07.015
4. Blas K, Feng FY, Halverson S, Lee V, Sabolch A, Olson K, Sandler HM, Hamstra DA (2010) Long-term androgen deprivation therapy improves metastasis free and cause-specific survival even in the setting of dose escalated radiation for localized prostate cancer. Int J Radiat Oncol Biol Phys 78(3):S125
5. Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh ACM, Oddens J, Poortmans PMP, Gez E, Kil P, Akdas A, Soete G, Kariakine O, Van der Steen-Banasik EM, Musat E, Pierart M, Mauer ME, Collette L, EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group (2009) Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360(24):2516-2527. doi: 10.1056/NEJMoa0810095
6. Crook J, Ludgate C, Malone S, Lim J, Perry G, Eapen L, Bowen J, Robertson S, Lockwood G (2004) Report of a multicenter Canadian phase III randomized trial of 3 versus 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 60(1):15-23. doi: 10.1016/j.ijrobp.2004.02.022
7. Crook J, Ludgate C, Malone S, Lim J, Eapen L, Bowen J, Lockwood G (2007) Report of a multicentre Canadian phase III randomized trial of 3 versus 8 months neoadjuvant androgen deprivation prior to standard dose radiotherapy for clinically localized prostate cancer. Radiother Oncol 84:S11
8. Crook J, Ludgate C, Malone S, Perry G, Eapen L, Bowen J, Robertson S, Lockwood G (2009a) Final report of multicenter Canadian Phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 73(2):327-333. doi: 10.1016/j.ijrobp.2008.04.075
9. Crook JM, Malone S, Perry G, Eapen L, Owen J, Robertson S, Ludgate C, Fung S, Lockwood G (2009b) Twenty-four-month postradiation prostate biopsies are strongly predictive of 7-year disease-free survival. Cancer 115(3):673-679
10. Cuenca X, Mazeron JJ (2006) Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Cancer/Radiother 10(1-2):91-92
11. Cuppone F, Bria E, Giannarelli D, Vaccaro V, Milella M, Nistico C, Ruggeri EM, Sperduti I, Bracarda S, Pinnaro P, Lanzetta G, Muti P, Cognetti F, Carlini P (2010) Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: meta-analysis of randomized trials. BMC Cancer 10:675. doi: 10.1186/1471-2407-10-675
12. Daly PE, Dunne MT, O'Shea CM, Finn MA, Armstrong JG (2012) The effect of short term neo-adjuvant androgen deprivation on erectile function in patients treated with external beam radiotherapy for localised prostate cancer: an analysis of the 4- versus 8-month randomised trial (Irish Clinical Oncology Research Group 97-01). Radiother Oncol 104(1):96-102. doi: 10.1016/j.radonc. 2012.05.001
13. D'Amico AV, Denham JW, Bolla M, Collette L, Lamb DS, Tai K-H, Steigler A, Chen M-H (2007a) Short- versus long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node-negative high-risk adenocarcinoma of the prostate. Cancer 109(10):2004-2010. doi: 10.1002/cncr.22628
14. D'Amico AV, Denham JW, Crook J, Chen M-H, Goldhaber SZ, Lamb DS, Joseph D, Tai K-H, Malone S, Ludgate C, Steigler A, Kantoff PW (2007b) Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 25(17):2420-2425. doi: 10.1200/jco.2006.09.3369
15. Denham JW, Steigler A, Lamb DS, Joseph D, Turner S, Matthews J, Atkinson C, North J, Christie D, Spry NA, Tai K-H, Wynne C, D'Este C (2011) Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol. 12(5):451-459. doi: 10.1016/s1470-2045(11)70063-8
16. Denham JW, Wilcox C, Joseph D, Spry NA, Lamb DS, Tai K-H, Matthews J, Atkinson C, Turner S, Christie D, Gogna NK, Kenny L, Duchesne G, Delahunt B, McElduff P (2012) Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial. Lancet Oncol 13(12):1260-1270. doi: 10.1016/s1470-2045(12)70423-0
17. Gleave ME, Goldenberg SL, Chin JL, Warner J, Saad F, Klotz LH, Jewett M, Kassabian V, Chetner M, Dupont C, Van Rensselaer S (2001) Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol 166(2):500-506 discussion 506-507
18. Gleave ME, Goldenberg SL, Chin JL, Saad F, Klotz LH, Jewett MAS, Dupont C (2009) Cuogp-95 randomized comparative study of 3 versus 8 months of neoadjuvant hormone therapy prior to prostatectomy: 7 year PSA relapse rates. J Urol 181(4):756
19. Gronberg H (2003) Prostate cancer epidemiology. Lancet 361(9360):859-864. doi: 10.1016/s0140-6736(03)12713-4
20. Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A (2011) GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol 64(4):380-382. doi: 10.1016/j.jclinepi.2010.09.011
21. Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, Horwitz EM, Lawton C, Rosenthal SA, Sandler HM, Shipley WU (2003) Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 21(21):3972-3978. doi: 10.1200/jco.2003.11.023
22. Higgins JPT, Green S (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org
23. Horwitz EM, Winter K, Hanks GE, Lawton CA, Russell AH, Machtay M (2001) Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term versus short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys 49(4):947-956
24. Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, Venkatesan V, Lawton CA, Rosenthal SA, Sandler HM, Shipley WU (2008) Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 26(15):2497-2504. doi: 10.1200/jco.2007.14.9021
25. Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason M (2009) Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev (4):CD006019. doi: 10.1002/14651858.CD006019.pub2
26. Laverdiere J, Gomez JL, Cusan L, Suburu ER, Diamond P, Lemay M, Candas B, Fortin A, Labrie F (1997) Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 37(2):247-252
27. Laverdiere J, Nabid A, De Bedoya LD, Ebacher A, Fortin A, Wang CS, Harel F (2004) The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer. J Urol 171(3):1137-1140. doi: 10.1097/01.ju.0000112979. 97941.7f
28. Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, Hug EB, Asbell SO, Grignon D (2005) Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61(5):1285-1290. doi: 10.1016/j.ijrobp.2004.08.047
29. Pu X-Y, Wang X-H, Wu Y-L, Wang H-P (2007) Comparative study of the impact of 3-versus 8-month neoadjuvant hormonal therapy on outcome of laparoscopic radical prostatectomy. J Cancer Res Clin Oncol 133(8):555-562. doi: 10.1007/s00432-007-0204-2
30. Roach M 3rd, DeSilvio M, Lawton C, Uhl V, Machtay M, Seider MJ, Rotman M, Jones C, Asbell SO, Valicenti RK, Han S, Thomas CR Jr, Shipley WS (2003) Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: radiation therapy oncology group 9413. J Clin Oncol 21(10):1904-1911. doi: 10.1200/jco.2003.05.004
31. Roach M 3rd, Bae K, Speight J, Wolkov HB, Rubin P, Lee RJ, Lawton C, Valicenti R, Grignon D, Pilepich MV (2008) Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 26(4):585-591. doi: 10.1200/jco.2007.13.9881
32. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics. CA Cancer J Clin 62(1):10-29. doi: 10.3322/caac.20138
33. Zapatero A, Alvarez A, Maldonado X, Guerrero A, Macias V, Cabeza A, San-Segundo CG, Casas F, Olive AP, Calvo FA (2008) Long-term versus short-term androgen deprivation combined with high-dose conformal radiotherapy (HDCRT) for patients with localized prostate cancer: first report on compliance, feasibility and SAFETY RESULTS FROM GICOR DART 01 trial. Ann Oncol 19(S8):viii197
34. Zapatero A, Alvarez A, Maldonado X, Guerrero A, Macias V, Cabeza A, San-Segundo CG, Casas F, Olive AP, Calvo FA (2009) Long-term versus short-term androgen deprivation combined with high-dose conformal radiotherapy (HDCRT) for patients with localized prostate cancer: first report on compliance, feasibility and safety results from GICOR DART 01 trial [Abstract No. 613P]. Ann Oncol 19(Suppl 8):197
35. Zapatero A, Guerrero A, Maldonado X, Alvarez A, Gonzalez San Segundo C, Cabeza A, Macias V, Casas F, Pedro-Olive A, Calvo FA (2010) Long-term versus short-term androgen deprivation combined with high-dose radiotherapy for localized prostate cancer: a Spanish multicenter phase III trial. J Clin Oncol 28(Suppl 1):e15036
36. Zapatero A, Garcia-Vicente F, Martin de Vidales C, Cruz Conde A, Ibanez Y, Fernandez I, Rabadan M (2011a) Long-term results after high-dose radiotherapy and adjuvant hormones in prostate cancer: how curable is high-risk disease? Int J Radiat Oncol Biol Phys 81(5):1279-1285. doi: 10.1016/j.ijrobp.2010.07.1975
37. Zapatero A, Guerrero A, Maldonado X, Alvarez A, Cabeza A, Gonzalez San Segundo C, Macias V, Casas F, Pedro-Olive A, Boladeras A (2011b) Long-term versus short-term androgen deprivation combined with high-dose radiotherapy for intermediate and high-risk prostate cancer: preliminary results of a gicor phase III randomized trial. Int J Radiat Oncol Biol Phys 81(2):S40
38. Zapatero A, Guerrero A, Maldonado X, Alvarez A, Gonzalez San Segundo C, Cabeza A, Macias V, Casas F, Pedro-Olive A, Villa S, Boladeras A, Vazquez de La Torre ML, Martin De Vidales C, Calvo FA (2011c) Phase III trial comparing long-term versus short-term androgen deprivation combined with high-dose radiotherapy for localized prostate cancer: GICOR protocol DART01/05. J Clin Oncol 29(Suppl 1):4580
39. Zapatero A, Guerrero A, Maldonado X, Alvarez A, Segundo CGS, Cabeza A, Macías V, Casas F, de Vidales CM, Calvo FA (2012) Long versus short-term androgen deprivation plus 78 Gy 3dcrt for prostate cancer: preliminary results Dart01/05 trial. Radiother Oncol 103:S18-S19. doi: 10.1016/s0167-8140(12)70387-0